Swaminathan 2011.

Methods	An open‐label, parallel arm, randomized controlled clinical trial conducted at 3 sites of the Tuberculosis Research Centre in Chennai, Vellore, and Madurai, located in southern India.
Participants	564 participants Inclusion criteria: People living with HIV who were at least 18 years of age with newly diagnosed TB, not pregnant and CD4+ cell counts < 250 cells/mm3. Exclusion criteria: previous ATT or ART for > 1month, HIV‐2 infection, major psychiatric illness, aspartate aminotransferase and alanine aminotransferase levels > 2.5 times the upper limit of normal and having a severe non‐HIV related disease.
Interventions	Didanosine (250/400 mg) + lamivudine (300 mg) + nevirapine (400mg after 14 days of 200 mg) or didanosine (250/400 mg) + lamivudine (300 mg) + efavirenz (600 mg)
Outcomes	Change in CD4 count, discontinuation rate, adherence rate, treatment failure, mortality, and adverse events.
Notes	Funded by the National AIDS Control Organization (New Delhi, India) and Indian Council of Medical Research (New Delhi, India). NCT00332306
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial authors performed permuted block randomisation.
Allocation concealment (selection bias)	Low risk	The trial conducted randomization centrally and statisticians prepared allocation codes in sealed and opaque envelopes for each site.
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Losses to follow‐up were balanced between groups and the trial authors reported reasons for losses to follow‐up. The trial authors used ITT analyses.
Selective reporting (reporting bias)	Low risk	The trial authors reported all outcomes of interest.
Baseline data reported?	Low risk	Demographic characteristics, CD4 count, and viral load.
Other bias	Low risk	We did not identify any other sources of bias.